Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in Opioid-Induced Constipation at Two Upcoming Scientific

Sucampo Announces Presentation of Results on AMITIZA(R) (lubiprostone) in
Opioid-Induced Constipation at Two Upcoming Scientific Conferences

BETHESDA, Md., Oct. 11, 2013 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc.
(Nasdaq:SCMP) ("Sucampo") today announced the presentation of three posters
evaluating AMITIZA® (lubiprostone) in opioid-induced constipation (OIC). Two
posters will be presented at the American College of Gastroenterology (ACG)
Annual Scientific Meeting in San Diego, California on October 13 and 15, 2013,
and the third poster will be presented at the American College of Clinical
Pharmacy (ACCP) Annual Meeting in Albuquerque, New Mexico on Wednesday,
October 16, 2013.

AMITIZA is the world's first chloride channel activator that increases
intestinal fluid secretion, softens stools, and increases intraluminal fluid
volume to initiate colonic transit and improve bowel function independent of
motility, thereby facilitating the passage of stool and alleviating symptoms
associated with chronic constipation.AMITIZA, via activation of apical ClC-2
channels in the intestinal epithelium, bypasses the antisecretory action of


The first poster listed below will be presented by Dr. Byron Cryer, lead
author and Professor of Medicine, University of Texas Southwestern Medical
Center, from 3:30 to 7:00 PM PT on Sunday, October 13, 2013. The second poster
will be presented by Dr. Shadreck Mareya, Sucampo's Director of Clinical
Program Management, on Tuesday, October 15, 2013 from 10:30 AM to 4:00 PM PT:

  *Spontaneous Bowel Movement Frequency Is Improved Over 12 Weeks of
    Lubiprostone Therapy in Opioid-Induced Constipation Patients Regardless of
    Gender, Age, or Race: Pooled Analysis of Three Well-Controlled Studies
    (Byron Cryer, MD, FACG, Shadreck Mareya, PhD, Taryn Joswick, BS, PMP,
    Gayle Dolecek, PD, MPH, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD) Poster
  *Lubiprostone Effectively Relieves Opioid-Induced Constipation in Patients
    Using Non-Diphenylheptane Opioids for Non-Cancer Pain: Pooled Analysis of
    3 Randomized Controlled Trials (Shadreck Mareya, PhD, Douglas A. Drossman,
    MD, MACG, Taryn Joswick, BS, PMP, Gayle Dolecek, PD, MPH, Yijun Sun, PhD,
    Ryuji Ueno, MD, PhD, PhD) Poster 1687


The following poster will be presented by Taryn Joswick, Sucampo's Vice
President of Clinical Development, during the Poster Session at ACCP on
Wednesday, October 16, 2013, between 8:00 AM to 10:00 AM MT:

  *Lubiprostone for Treatment of Opioid-Induced Constipation Does Not
    Interfere With Opioid Analgesic Effects in Patients With Non-Cancer Pain
    (Egilius L. H. Spierings, MD, PhD, Taryn Joswick, BS, PMP, Shadreck
    Mareya, PhD, Yijun Sun, PhD, Ryuji Ueno, MD, PhD, PhD) Poster 137

About lubiprostone

Lubiprostone is available under the brand name AMITIZA® in the U.S.AMITIZA
capsules are indicated for the treatment of chronic idiopathic constipation
(CIC) in adults and opioid induced constipation (OIC) in adults with chronic,
non-cancer pain (24 mcg twice daily). The effectiveness in patients with OIC
taking diphenylheptane opioids (e.g., methadone) has not been established.
AMITIZA is also indicated for irritable bowel syndrome with constipation
(IBS-C) in women > 18 years old (8 mcg twice daily).

Important Safety Information

  *AMITIZA (lubiprostone) is contraindicated in patients with known or
    suspected mechanical gastrointestinal obstruction. Patients with symptoms
    suggestive of mechanical gastrointestinal obstruction should be thoroughly
    evaluated by the treating healthcare provider (HCP) to confirm the absence
    of such an obstruction prior to initiating AMITIZA treatment.
  *Patients taking AMITIZA may experience nausea. If this occurs, concomitant
    administration of food with AMITIZA may reduce symptoms of nausea.
    Patients who experience severe nausea should inform their HCP.
  *AMITIZA should not be prescribed to patients that have severe diarrhea.
    Patients should be aware of the possible occurrence of diarrhea during
    treatment. Patients should be instructed to discontinue AMITIZA and inform
    their HCP if severe diarrhea occurs.
  *Patients taking AMITIZA may experience dyspnea within an hour of first
    dose. This symptom generally resolves within three hours, but may recur
    with repeat dosing. Patients who experience dyspnea should inform their
    HCP. Some patients have discontinued therapy because of dyspnea.
  *In clinical trials of AMITIZA (24 mcg twice daily vs placebo; N=1113 vs
    N=316, respectively) in patients with CIC, the most common adverse
    reactions (incidence > 4%) were nausea (29% vs 3%), diarrhea (12% vs <
    1%), headache (11% vs 5%), abdominal pain (8% vs 3%), abdominal distension
    (6% vs 2%), and flatulence (6% vs 2%).
  *In clinical trials of AMITIZA (24 mcg twice daily vs. placebo; N=860 vs.
    N=632) in patients with OIC, the most common adverse reactions (incidence
    > 4%) were nausea (11% vs 5%) and diarrhea (8% vs 2%).
  *In clinical trials of AMITIZA (8 mcg twice daily vs. placebo; N=1011 vs.
    N=435, respectively) in patients with IBS-C the most common adverse
    reactions (incidence > 4%) were nausea (8% vs 4%), diarrhea (7% vs 4%),
    and abdominal pain (5% vs 5%).
  *Concomitant use of diphenylheptane opioids (e.g., methadone) may interfere
    with the efficacy of AMITIZA.
  *The safety of AMITIZA in pregnancy has not been evaluated in humans. Based
    on animal data, AMITIZA may cause fetal harm. AMITIZA should be used
    during pregnancy only if the potential benefit justifies the potential
    risk to the fetus. Caution should be exercised when AMITIZA is
    administered to a nursing woman. Advise nursing women to monitor infants
    for diarrhea.
  *Reduce the dosage in CIC and OIC patients with moderate and severe hepatic
    impairment. Reduce the dosage in IBS-C patients with severe hepatic

For further information, please visit complete
Prescribing Information.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones
was first discovered by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman,
Chief Executive Officer, Chief Scientific Officer, and co-founder. Prostones,
naturally occurring fatty acid metabolites that have emerged as promising
compounds with unique physiological activities, can be targeted for the
treatment of unmet or underserved medical needs. For more information, please

The Sucampo logo and the tagline, The Science of Innovation, are registered
trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Sucampo Forward-Looking Statement

This press release contains "forward-looking statements" as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management's current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo's
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo's patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or regulatory
actions. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Sucampo undertakes no obligation to
publicly update any forward-looking statement, whether as a result of new
information, future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many uncertainties that
affect Sucampo's business, particularly those mentioned in the risk factors
and cautionary statements in Sucampo's most recent Form 8-K and 10-K, which
Sucampo incorporates by reference.

Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo

Twitter LinkedIn

CONTACT: Silvia Taylor
         Senior Vice President, IR, PR, and
         Corporate Communications

Sucampo Logo
Press spacebar to pause and continue. Press esc to stop.